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Preservation of Cardiac Function by Coronary Thrombolysis During
Acute Myocardial Infarction: Fact or Myth?
MARIO S. VERANI, MD, FACC, ROBERT ROBERTS, MD, FACC
Houston, Texas
Since the report by Rentrop et al. (l ) showing that intra-
coronary thrombolysis with streptokinase is feasible in pa-
tients with acute myocardial infarction, emergency coronary
thrombolysis and recanalization have challenged the tradi-
tional therapeutic regimen that has prevailed for the last
quarter of a century. Coronary recanalization is about to
revolutionize the treatment of acute myocardial infarction
and has taken on forms that will extend this technique even
to the primary care community hospital.
Several thousands of patients have undergone coronary
thrombolysis, yet the question of long-term efficacy remains
unanswered. Will it shorten or prolong life? Does it preserve
myocardial function? Which patients, if any, benefit most?
What is the best method to provide rapid, consistent coro-
nary recanalization in the shortest possible time? Although
these questions will only be answered after completion of
large scale, randomized studies (2), considerable relevant
experimental and clinical data are available. In this review,
we address the available information and uncertainties deal-
ing with the effects of coronary thrombolysis and recanal-
ization on myocardial function.
Experimental Evidence That Coronary
Recanalization Preserves Myocardial
Function
The bulk of information gathered from diverse animal
species overwhelmingly indicates that early reperfusion of
ischemic myocardium leads to myocardial salvage and re-
covery of regional myocardial function. In those experi-
ments, regional ventricular function was precisely quantified
by implanted ultrasonic crystals, a sophistication that ob-
viously is not possible in humans. The extent of recovery
depends on the duration of myocardial ischemia. Reperfu-
sion after 5 to IS minutes of coronary occlusion in the dog
leads to virtual complete salvage of myocardium and sig-
nificant salvage is still possible even after 3 hours of oc-
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c1usion (3). Essentially no improvement of regional function
results when perfusion is restored after 3 hours of ischemia.
In addition to the duration of ischemia, other factors play
a role in the extent and rate of recovery of ventricular func-
tion. These include the size of the vascular bed perfused by
the involved coronary artery, the coronary collateral flow
and, in humans, the extent of disease in vessels other than
that directly related to the area of damage. Despite salvage
from irreversible injury, the previously ischemic myocar-
dium does not function immediately. The "stunned myo-
cardium" requires time to recover and this may range from
several hours to days (3). Although reperfusion in the ex-
perimental animal clearly curtails the extent of irreversible
injury and improves survival, there is evidence that reper-
fusion itself may also induce myocardial injury (4,5). In
1974 we reported (6) that reperfusion may increase myo-
cardial damage. This finding has since been confirmed by
several investigators (7,8). There is a clear-cut agreement
among researchers that reperfusion is followed by temporary
stunning of the myocardium, but whether further irreversible
injury is induced by reperfusion remains controversial (9,10).
The mechanism for the so-called postischemic stunning or
delayed recovery of ventricular function remains unknown,
the most recent suggestion being that reintroduction of ox-
ygen to the ischemic cell generates toxic, oxygen free rad-
icals (4,5,11). Many other factors, of course, have been
postulated, including the no-reflow phenomenon.
Ventricular Function and Thrombolysis in
Clinical Studies
Several clinical trials have now been performed using
either intracoronary or intravenous streptokinase and, more
recently, intravenous recombinant tissue plasminogen ac-
tivator (rt-PA). The effect of reperfusion on left ventricular
function in the observational trials that used intracoronary
streptokinase (12-29) is shown in Table I. A consistent
observation in those trials was the lack of dramatic im-
provement in left ventricular ejection fraction and the wide
range of ejection fraction values after thrombolysis. Striking
improvement in left ventricular function was observed only
occasionally. In the majority of these trials, which were
0735-1097/87/$3.50





Table 1. Effect of Intracoronary Thrombolytic Treatment on Ventricular Function (nonrandomized trials)*
No. Time to Change in EF (units)
First Author of Intervention Assessment Before Regional
& Ref. Pts. (hours) Technique Intervention Nonrecanalized Recanalized Function
Cowley (12) II 5.5 Contrast Done ~ 15t lOt Improved
Ganz (13) 20 26 Nuclear Not done Not done Not done Improved
Rentrop (14) 55 <3.0 to >6.0 Contrast Done Not done 20t Improved
Rentrop (15) 27 5.6 Contrast Done Not done 5.5t Not done
Cernigliaro (16) 15 <3 Contrast Done Not done 8.0t Improved
Schwarz (17) 27 oto 8 Contrast Done -4.4 5.4 Improved
Smalling (18) 89 oto 18 Nuclear Done 1.0 8t Not done
Cribier (19) 58 3.6 Contrast Done -12 2.0 Improved
Rentrop (20) 125 <2 to >6 Contrast Done -2.5 2.4t Not done
Sheehan (21) 52 <3 Contrast Not done -7t -4 Improved
Stack (22) 24 4.8 Contrast Done -4 3.0 Improved
Charuzi (23) 23 <3 Echo Done Not done Not done Improved
Ferguson (24) 77 <9 Nuclear Not done 5 6 Not done
Murakami (25) 30 oto >10 Contrast Not stated Not done Not done Improved
Saito (26) 30 2 to 8 Contrast Done I 15.6t Improved
Sato (27) 38 <6 Contrast Done -6t 6t Improved
Sheehan (28) 47 <3 Contrast Not done Notdone Not done Improved
Timmis (29) 69 <5 Contrast Not done Not done 6.2t Improved
*Only trials with information on left ventricular function are listed. tp < 0.05. Echo = echocardiography: EF = ejection fraction: Pts. = patients.
uncontrolled and nonrandomized, the disappointing results
probably relate to the time interval from onset of symptoms
to intervention, which was often >6 hours (Table I). Re-
striction of analysis to patients with successful thrombolysis
showed a consistent trend of improved left ventricular func-
tion. In several series (17,21,22), improvement in regional
ventricular function in the infarct area was often docu-
mented, despite a lack of increase in global ejection fraction.
There was also a definite trend indicating that the earlier
the reperfusion, the more likely it was to be associated with
improvement of left ventricular function (17,21,25).
Intracoronary versus intravenous streptokinase ther-
apy. The results of the prospective, randomized trials (30-36)
in which the thrombolytic agents were administered through
the intracoronary route are summarized in Table 2. There
was little or no improvement in the global ejection fraction
of treated patients compared with that of the control group.
However, in the two largest trials (33,34) left ventricular
function was not assessed before and after the intervention;
instead, the predischarge ejection fraction of the control and
streptokinase groups were compared. Again, as in the non-
randomized trials, streptokinase therapy was not initiated
until at least 3 hours after the onset of symptoms, which
probably precluded any dramatic improvement in left ven-
tricular function. The delay before the initiation of therapy
was due primarily to time spent mobilizing personnel re-
quired for emergency cardiac catheterization. To overcome
this difficulty, investigators initiated intravenous strepto-
kinase therapy; results of those trials (37-44) are summa-
rized in Table 3. Most of these trials, including the two
randomized European trials, have shown only modest im-
provement in global or regional ventricular function. Will
Table 2. Effect of Thrombolytic Treatment on Ventricular Function (randomized trials)"
No. Time to Change in EF
First Author of Intervention Before Change in EF (units) Regional (units)
& Ref. Pts. (hours) Technique Intervention Nonrecanalized Recanalized Function Control Treated
Anderson (30) 50 4 Nuclear. echo Done Not done Not done Improved - 3.0 3.9t
Khaja (31) 40 5.4 Nuclear, contrast Done Not done Not done Improved +1 0
Leiboff (32) 43 4.8 Nuclear Notdone - 1.8 -I.I Not done -0.4 -2.8
Rentrop (33) 47 6.1 Nuclear Done Not done Not done Not done -1.4 2.1
Ritchiej (34) 207 4.6 Nuclear Not done Not done Not done Not done Notdone Not done
Raizner (35) 54 5.6 Nuclear Done -6 7t Improved 2 3
Vermeerf (36) 488 >4 Nuclear Not done Not done Not done Notdone Notdone Not done
*Only trials with information on left ventricular function are listed. tp < 0.05. :j:Difference in late ejection fraction between control and treated
groups not significant. ~Intravenous and intracoronary therapy used. Difference in late ejection fraction between control and treated group significant (43
vs. 50%. p > 0.0001). Abbreviations as in Table I.
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Table 3. Effect of Intravenous Thrombolytic Treatment on Ventricular Function
No. Time to Change in EF (units)
First Author of Intervention Before Regional
&Ref. Pts. (hours) Technique Intervention Nonrecanalized Recanalized Function
Schroder (37) 93 <6 Contrast Done -3 5 Improved
Rogers* (38) 63 7 Contrast, nuclear Done - [2t 0 No change
Schwarz* (39) 55 <6 Contrast Done -5t [5t Improved
Spann (40) 43 <6 Contrast Done -[ 9t Improved
Mathey* (4[) 52 <3 Contrast Not done Not done 7 Improved
Valentine* (42) 164 6 Nuclear Not done 3.8 9.5t Not done
ISAM:j:§ (43) [,74[ <6 Contrast Not done Not done Not done Improved
Sitnoohs*§ (44) 533 3.2 Nuclear] Not done 1.3 3.7t Not done
*Series with both intracoronary and intravenous streptokinase or urokinase. tp < 0.05. :j:Late ejection fraction higher (p < 0.005) in treated than in
control group. §Randomized series. In ISAM series, treated group had a higher ejection fraction than control patients at 4 weeks (56.8 vs. 53.9%, P <
0.005). [Radionuclide angiography done on days 2 to 4 and 10 to 20. Abbreviations as in Table I.
the realization that "time is of the essence" naturally lead
to improved ventricular function in future trials? Several
factors must be taken into account, some prospectively, if
we are to provide quantitative data on ventricular function.
Effect of Thrombolytic Therapy on
Ventricular Function
Before we recommend to the medical community the
routine use of intravenous thrombolytic therapy, we must
demonstrate its efficacy not just in restoring coronary pat-
ency but also in reducing mortality and morbidity, Although
long-term survival would be the most definitive end point
for assessing the results of thrombolysis, it has several draw-
backs. First, a sample size of several thousand patients
would be required for a trial to unequivocably demonstrate
or negate a beneficial effect on survival. Second, the in-
creasing use of angioplasty in conjunction with or subse-
quent to thrombolysis may preclude assessment of the effect
of thrombolysis itself, even on acute rnortality. Ventricular
function as an end point thus has great appeal because I)
it has been proved to be a reliable predictor of short- and
long-term mortality; 2) it requires far fewer patients to dem-
onstrate efficacy than does mortality; 3) the effect of throm-
bolysis can be determined acutely; and 4) it may be the only
feasible and reliable end poirit to assess thrombolysis as
such. In view of the recent Gissi trial (45) a placebo group
is now an endangered species, as reflected in phase II of
the TIMI trial, which was initiated in May 1986 after elim-
inatiori of the placebo group. In future trials, the influence
of thrombolysis or angioplasty, or both, on short- or long-
term mortality will be assessed only in relation to historical
or estimated future mortality rates, Therefore, a change in
ventricular function, as assessed serially in each patient,
appears to be the only trial end point, whether evaluating
thrombolysis or angioplasty, that will be based on two or
more values determined sequentially in the same patient.
In view of the Gissi trial (45), which demonstrated a 50%
reduction in mortality in patients treated within the first hour,
the reality of reduced mortality as the universal consequence
of thrombolysis is likely to be near, as is improved ven-
tricular function. How shall we best assess ventricular func-
tion? Early intervention in future trials will likely exclude
any invasive assessment before therapy, Ventricular func-
tion will be assessed noninvasively, preferably before and
after thrornbolytic therapy, though initial assessment im-
mediately after instituting therapy will likely be a reasonable
compromise to avoid delaying treatment. Will the inherent
limitation of the clinical trial or the imprecision of the meth-
ods used preclude one from demonstrating improved ven-
tricular function?
Limitations Inherent in the Clinical Trial
Thrombolytic trials to date have given us at least two
axioms: I) acute transmural infarction is associated with
coronary thrombosis (and this time the latter concept is here
to stay); and 2) to salvage ischemic myocardium during
evolving myocardial infarction, we must restore flow within
3 to 4 hours, There is also general agreement that the de-
finitive statement on efficacy of thrombolytic therapy, whether
for improving ventricular function or survival, must come
from the large randomized trial analyzed on the basis of
intention to treat. This form of analysis does not take into
account several factors that would preclude or minimize the
beneficial effect. All patients enrolled with suspected acute
myocardial infarction will undergo a similar analysis. How-
ever, we know that even if ST segment elevation is required
as an entry criterion, at least 15 to 20% of patients will not
develop infarction. This is coupled with the fact that throm-
bolytic therapy will be successful in only 65 to 70% of
patients receiving intravenous rt-PA and in 50% receiving
streptokinase. Furthermore, patients presenting with sub-
total coronary occlusion or having "spontaneous early re-
perfusion" may exhibit little depression in ventricular func-
tion.





On the basis of results of the trials to date, even if one
abandons the intention to treat principle and assesses only
those patients with complete occlusion who undergo suc-
cessful thrombolysis, little improvement is expected in pa-
tients whose initial ejection fraction after the onset of symp-
toms remains in the normal range. It may well be that if
damage is minimal to moderate and there is compensatory
hyperkinesia of the noninvolved myocardium, the ejection
fraction remains near normal. Reperfusion may be followed
by withdrawal of the compensatory hyperkinesia and hence
the ejection fraction does not change, despite improvement
in the contraction of the ischemic myocardium. One is more
likely to see greater improvement in patients with more
severely depressed ventricular function, in whom compen-
satory mechanisms are inadequate to maintain a normal
ejection fraction, such as those with extensive anterior in-
farction. So we must be concerned that patients exhibiting
no effect from thrombolytic therapy because they did not
have myocardial infarction or complete occlusion or in whom
therapy was unsuccessful do not dilute the beneficialeffects
of successful therapy in appropriate patients.
The presence of collateral circulation also appears to
afford greater recovery offunction (1,38,39), presumably
by maintaining cell viability until effective thrombolysis
occurs. Conversely, it has been observed, though not well
documented, that patients undergoing successful thrombo-
lytic therapy who are left with residual high grade coronary
stenosis exhibit less improvement in regional ventricular
function (28).
Role of thrombolytic therapy combined with anglo-
plasty or surgery. Assessment of the effect of thrombo-
lysis, even acutely, may be complicated by available me-
chanical options for recanalization, such as angioplasty or
surgery, which have a high likelihood of being used acutely
in conjunction with thrombolytic therapy. On the basis of
preliminary results of the recent TAMI trial (46), such com-
bination therapy has been proclaimed superior to throm-
bolytic therapy alone, although the changes in ventricular
function in patients undergoing emergent as opposed to elec-
tive angioplasty have yet to be reported in this study. It
would be most applicable for the community needs if a
thrombolytic agent could be administered and patency main-
tained so that angioplasty could be delayed for the 24 to 48
hours required to transport the patient to a larger medical
center where appropriate angioplasty could be performed
by experienced personnel. The complication rate of per-
cutaneous transluminal coronary angioplasty in experienced
hands during acute infarction has been generally low, the
patency rate has been high and the severity of residual coro-
nary stenosis has been decreased (47,48). However, the 20
to 30% restenosis rate after angioplasty will temper the long-
term results. Initial trials, comparing thrombolytic therapy
alone with coronary angioplasty (associated or not with
thrombolytic agents), suggest greater improvement of left
ventricular function when angioplasty is performed acutely
(47,48). The precise interval during which angioplasty should
be performed, namely, whether acutely or within days, is
far from resolved and is now being assessed in phase II of
the Thrombolysis in Myocardial Infarction (TIM!) Trial.
Results in patients receiving angioplasty within 2 hours of
thrombolytic therapy will be compared with thoseof patients
undergoing angioplasty 18 to 48 hours after thrombolytic
therapy.
Limitations Inherent in the Assessment of
Ventricular Function
Left ventricular ejection fraction has been the functional
variable most commonly assessed after coronary recanali-
zation. However useful as an index of global left ventricular
performance, it is importantly dependent on left ventricular
preload and afterload, which are by no means constant in
patients with acute infarction. Various medications such as
diuretics and vasodilators, commonly used in patients with
acute myocardial infarction, also affect these variables. Fur-
thermore. although the ejection fraction affords a convenient
variable to assess global function, it does not necessarily
reflect regional myocardial function; yet myocardial infarc-
tion is almost always a regional disease. Quantification of
regional function by radionuclide angiography as well as
with contrast angiography or two-dimensional echocardi-
ography is plagued by an unresolved problem, namely, ro-
tation of the left ventricular center of gravity during cardiac
contraction. Echocardiography, although the most readily
available technique, still offers suboptimal endocardial edge
definition, which hampers quantification of wall motion.
Radionuclide angiography may be the best available means
to quantify left ventricular ejection fraction, because it is
the only technique that is independent of ventricular ge-
ometry. However, there is a pressing need for improvement
in the quantification of regional ventricular function with
radionuclide angiography.
Right ventricular function in myocardial infarction.
To date, radionuclide angiography has in general been per-
formed to assess only left ventricular function after throm-
bolysis. The effect of this therapy on right ventricular func-
tion has only recently been addressed (49,50). Its importance
lies in the observation that right ventricular infarction is
quite frequent in patients with inferior wall infarction (51-58)
and that right ventricular damage may be extensive, which
with concomitant left ventricular damage may lead to car-
diogenic shock and death (58,59). At the present time, it
is difficult to quantify precisely the global right ventricular
ejection fraction by either blood pool radionuclide angi-
ography or echocardiography, let alone regional right ven-
tricular function. Frequently, it is stated that thrombolysis
appears less beneficial in inferior than in anterior infarction;
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perhaps we should wait until we have assessed its effect on
right ventricular function before making such judgment.
Radionuclideangiography using the first pass technique and
a multicrystal gamma camera is currently the best means to
assess right ventricular function, but it is hampered by the
high cost and limited portability of the multicrystal camera.
A newly described, portable multiwire gamma camera (60),
utilizingthe short-lived radionuclide tantalum-178, provides
high resolution first pass imaging of the right and left ven-
tricle and may afford a means to conduct bedside quanti-
tative assessment of right and left ventricular function.
Role of myocardial stunning and reinfarction. The
interval over which left ventricular function should be as-
sessed is unclear because stunning may recover in 24 to 48
hours or it may require several days; nevertheless, com-
parison of studies obtained on or shortly after admission
and 7 to 10 days later should be satisfactory. Another major
concern is coronary reocclusion with reinfarction. Follow-
up studies in the TIMI trial (61), as well as in several other
trials (32,33,62-65) , have shown that the incidenceof rein-
farction from reocclusion, if no other intervention is per-
formed , is in the range of 20 to 30%. This of course would
cause further deterioration in ventricular function and, when
combined with patients without reinfarction , the benefit from
reperfusion would be diluted or even masked completely.
Recommendations for the Future
Coronary thrombolysis undoubtedly is a promising treat-
ment modality for patients with acute myocardial infarction.
However, because the risk of bleeding is considerable with
this therapy, it is incumbent on investigators to prove con-
clusively that the benefits outweigh the risks. Short-term
mortality has been shown to be decreased by thrombolytic
treatment in recent randomized series (45,66). This bene-
ficial effect on mortality will be easier to demonstrate in
future trials if investigators focus on subsets of patients at
high risk, such as those with extensive infarction or car-
diogenic shock. Despite the somewhat disappointingresults
of the small randomized series reported thus far, the short-
term effects of thrombolysis on ventricular function should
be beneficial, providedthat recanalizationis achievedwithin
3 hours of coronary occlusion. To realize the full benefits
of thrombolysis in the largest possible populationwith acute
myocardial infarction, we must aim for the administration
of thrombolytic agents by paramedic personnel in the pa-
tients' home or work site. In this regard, the report of Koren
et al. (67) showing that patients treated < 1.5 hours after
onset of pain had significantly higher global and regional
ejection fractions than those of patients treated I .5 to 4 hours
after onset of pain is encouraging. This improvement in
function, which may occur gradually over several days, is
entirely consistent with the bulk of experimental data. To
document improved performance, global left ventricular
ejection fraction cannot be relied on as the sole variable but
shouldbe combined withquantitativeassessmentof regional
function. Furthermore, in patients with inferior infarction
the right ventricular function should be routinely assessed.
Definitive evaluation of the effects of reperfusion on the
long-term mortality and on the preservation of left ventric-
ular function-they must be intimately related-will have
to await the results of large, long-term, randomized studies,
in which the thrombolytic agent is administered within the
first 2 to 3 hours of onset of myocardial infarction. The
additional improvement that may result by combining
thrombolysis with other interventions designed to improve
myocardial reperfusion (by angioplasty or surgery), de-
crease myocardial oxygen demand (for example, beta-ad-
renergic blockade) or minimize reperfusion injury (for ex-
ample, administration of free radical scavengers) also remains
to be proved and will be fruitful areas for research in the
years to come. Until then, we believe that preservation of
cardiac function by coronary thrombolysis during acute
myocardial infarction is a fact-but surely in need of con-
firmation .
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